Genetic polymorphisms of the β-adrenergic system: Association with essential hypertension and response to β-blockade

Pharmacogenomics Journal

Volumn 4, Issue 3, 2004, Pages 154-160

  Filigheddu, F ^a   Reid, J E ^b   Troffa, C ^a   PinnaParpaglia, P ^c   Argiolas, G ^a   Testa, A ^d   Skolnick, M ^b   Glorioso, N ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b Myriad Genetic Laboratories   (United States)

^c Emergency Department   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOSINE; FOSINOPRIL; G PROTEIN COUPLED RECEPTOR; GENOMIC DNA; GUANINE; HYDROCHLOROTHIAZIDE; THYMINE;

ADRENERGIC SYSTEM; ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA;

EID: 2942731307     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500247     Document Type: Article

References (42)

1. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265: 2037-2048.
2. Glorioso N, Filigheddu F, Troffa C, Soro A, Parpaglia PP, Tsikoudakis A et al. Interaction of alpha(1)-Na,K-ATPase and Na,K,2Cl-co-transporter genes in human essential hypertension. Hypertension 2001; 38: 204-209.
3. Ferrari P, Bianchi G. The genomics of cardiovascular disorders: therapeutic implications. Drugs 2000; 559: 1025-1042.
4. Liggett SB. Pharmacogenetics of beta-1 and beta-2-adrenergic receptors. Pharmacology 2000; 61: 167-173.
5. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001; 104: 187-190.
6. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99: 233-238.
7. Xie HG, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V et al. Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. Clin Pharmacol Ther 2000; 67: 670-675.
8. Kotanko P, Binder A, Tasker J, DeFreitas P, Kamdar S, Clark AJ et al. Essential hypertension in African Caribbeans associates with a variant of the β2-adrenoceptor. Hypertension 1997; 30: 773-776.
9. Jia H, Sharma P, Hopper R, Dickerson C, Lloyd DD, Brown MJ. Beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens 2000; 18: 687-693.
10. Pamies-Andreu E, Garcia-Lozano R, Palmero-Palmero C, Garcia-Morillo S, Alonso-Arcas A, Stiefel P et al. Genetic variation in the beta-3-adrenergic receptor in essential hypertension. Life Sci 2000; 67: 391-397.
11. Ringel J, Kreutz R, Distler A, Sharma AM. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus. Am J Hypertens 2000; 13: 1027-1031.
12. Tonolo G, Melis MG, Secchi G, Atzeni MM, Angius MF, Carboni A et al. Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population. J Hypertens 1999; 17: 33-38.
13. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73: 366-371.
14. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52.
15. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D et al. Association of the G(s) α gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34: 8-14.
16. Brand E, Herrmann SM, Nicaud V, Ruidavets JB, Evans A, Arveiler D et al. The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. Hypertension 1999; 33: 1175-1178.
17. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 45-48.
18. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37(Part 2): 739-743.
19. Muntner P, He J, Roccella EJ, Whelton PK. The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension 2002; 39: 897-902.
20. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414-9419.
21. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995-999.
22. Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000; 139: 537-542.
23. Thursz MR, Thomas HC, Brian MG, Hill AVS. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997; 17: 11-12.
24. Wang CH, Schilling RF. Myocardial infarction and thalassemia trait: an example of heterozygote advantage. Am J Hematol 1995; 49: 73-75.
25. Mitchison NA. Polymorphism in regulatory gene sequences. Genome Biol 2000; 2: http://genomebiology.com/2000/2/1/ comment/2001.1-2001.6.
26. Tomaszewski M, Brain NJ, Charchar FJ, Wang WY, Lacka B, Padmanabahn S et al. Essential hypertension and beta2-adrenergic receptor gene: linkage and association analysis. Hypertension 2002; 40: 286-291.
27. Castellano M, Rossi F, Giacche M, Perani C, Rivadossi F, Muiesan ML et al. Beta(2)-adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension 2003; 41: 361-367.
28. Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay. Lancet 1999; 353: 897.
29. Moser M. Relative efficacy of, and some adverse reactions to, different antihypertensive regimens. Am J Cardiol 1989; 63: 2B-7B.
30. Siffert W, Rosskopf D, Moritz A, Wieland T, Kaldenberg-Stasch S, Kettler N et al. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 1995; 96: 759-766.
31. Pietruck F, Moritz A, Montemurro M, Sell A, Busch S, Rosskopf D et al. Selectively enhanced cellular signaling by Gi proteins in essential hypertension. G alpha i2, G alpha i3, G beta 1, and G beta 2 are not mutated. Circ Res 1996; 79: 974-983.
32. Benjafield AV, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ. G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 1998; 32: 1094-1097.
33. Bianchi G, Staessen JA, Ferrari P. Pharmacogenomics of primary hypertension - the lessons from the past to look toward the future. Pharmacogenomics 2003; 4: 279-296.
34. Kardia SL. Context-dependent genetic effects in hypertension. Curr Hypertens Rep 2000; 2: 32-38.
35. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34(Part 1): 649-654.
36. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-1238.
37. Sham P. Statistics in Human Genetics. John Wiley and Sons: New York 1998.
38. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309.
39. Shifman S, Darvasi A. The value of isolated populations. Nat Genet 2001; 28: 309-310.
40. Cappello N, Rendine S, Griffo R, Mameli GE, Succa V, Vona G et al. Genetic analysis of Sardinia: I. data an 12 polymorphisms in 21 linguistic domains. Ann Hum Genet 1996; 60(Part 2): 125-141.
41. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997; 100: 3005-3013.
42. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. BMJ 1983; 286: 1489-1493.